MY-943
Based on 1 Customer Validation
MY-943 is a potent tubulin polymerization and LSD1 inhibitor with anticancer activity. MY-943 induces G2/M phase arrest and apoptosis, and inhibits cell migration. MY-943 can be used for gastric cancer research.
For research use only. We do not sell to patients.
- Purity : 98.01%
- CAS No.: 3043676-46-3
- Formula: C30H36N4O6S2
- Molecular Weight:612.76
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
253.9 nM
Compound: I-25; MY-943
|
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 36940611] |
| DU-145 | IC50 |
49.9 nM
Compound: I-25; MY-943
|
Antiproliferative activity against human DU-145 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human DU-145 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 36940611] |
| ECa-109 cell line | IC50 |
114.4 nM
Compound: I-25; MY-943
|
Antiproliferative activity against human EC109 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human EC109 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 36940611] |
| HCT-116 | IC50 |
0.044 μM
Compound: I-25; MY-943
|
Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 36940611] |
| HGC-27 | IC50 |
24.5 nM
Compound: I-25; MY-943
|
Antiproliferative activity against human HGC-27 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human HGC-27 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 36940611] |
| Huh-7 | IC50 |
47.9 nM
Compound: I-25; MY-943
|
Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 36940611] |
| KYSE-450 | IC50 |
0.03 μM
Compound: I-25; MY-943
|
Antiproliferative activity against human KYSE-450 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human KYSE-450 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 36940611] |
| MCF7 | IC50 |
34.4 nM
Compound: I-25; MY-943
|
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 36940611] |
| MGC-803 | IC50 |
0.017 μM
Compound: I-25; MY-943
|
Antiproliferative activity against human MGC-803 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human MGC-803 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 36940611] |
| NCI-H520 | IC50 |
22.5 nM
Compound: I-25; MY-943
|
Antiproliferative activity against human NCI-H520 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human NCI-H520 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 36940611] |
| PC-3 | IC50 |
44.6 nM
Compound: I-25; MY-943
|
Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 36940611] |
| SGC-7901 | IC50 |
19.5 nM
Compound: I-25; MY-943
|
Antiproliferative activity against human SGC-7901 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human SGC-7901 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 36940611] |
| SMMC-7721 | IC50 |
27 nM
Compound: I-25; MY-943
|
Antiproliferative activity against human SMMC-7721 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human SMMC-7721 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 36940611] |
| TE-1 | IC50 |
31.4 nM
Compound: I-25; MY-943
|
Antiproliferative activity against human TE-1 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human TE-1 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 36940611] |
In Vitro
MY-943 exhibits the anti-proliferative activities against three kinds of cancer cells with IC50 values of 0.019 μM for MGC-803, 0.044 μM for HCT-116 and 0.030 μM for KYSE450[1].
MY-943 (10, 20, 30 nM; 20, 40, 48, 60 h) dose-dependently and time-dependently inhibits the cell viability of MGC-803 and SGC-7901 cells[1].
MY-943 (1, 5, 10 μm; 48 h) dose-dependently weakens the alkylation of β-tubulin in the presence of EBI, and prevents the formation of β-tubulin:EBI adduct band in MGC-803 and SGC-7901 cells[1].
MY-943 (10, 20, 30 nM; 8, 16, 24 nM; 48 h) concentration-dependently inhibits tubulin polymerization in MGC-803 and SGC-7901 cells[1].
MY-943 (10, 20, 30 nM; 8, 16, 24 nM; 48 h) dose-dependently induces cell apoptosis[1].
MY-943 dose-dependently down-regulates the expression levels of Bcl-2 and Mcl-1 (anti-apoptotic proteins), and dose-dependently increases the expression levels of cleaved Caspase-3 and Caspase-7[1].
MY-943 (10, 20, 30 nM; 8, 16, 24 nM; 48 h) dose-dependently down-regulates the expression levels of Weel, CyclinB1 and CDC2, and dose-dependently increases the expression levels of p-Histone H3, H3K4me1 and H3K4me2[1].
MY-943 (10, 20, 30 nM; 8, 16, 24 nM; 48 h) effectively and dose-dependently induces G2/M phase arrest[1].
MY-943 (10, 20, 30 nM; 8, 16, 24 nM; 48 h) significantly inhibits the migration ability of gastric cancer cells MGC-803 and SGC-7901[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MGC-803 and SGC-7901 cells
-
Concentration:10, 20, 30 nM
-
Incubation Time:20, 40, 48, 60 h
-
Result:Dose-dependently inhibited the cell viability of MGC-803 and SGC-7901 cells (10, 20, 30 nM; 48 h). Time-dependently inhibited the cell viability of MGC-803 and SGC-7901 cells (10, 20, 30 nM; 20, 40, 60 h).
-
Cell Line:MGC-803 and SGC-7901 cells
-
Concentration:1, 5, 10 μM
-
Incubation Time:48 h
-
Result:Dose-dependently weakened the alkylation of β-tubulin in the presence of EBI, and prevented the formation of β-tubulin:EBI adduct band in MGC-803 and SGC-7901 cells.
-
Cell Line:MGC-803 and SGC-7901 cells
-
Concentration:10, 20, 30 nM for SGC-7901 cells; 8, 16, 24 nM for MGC-803 cells
-
Incubation Time:48 h
-
Result:Concentration-dependently inhibited tubulin polymerization in MGC-803 and SGC-7901 cells, thereby destroying the microtubule network.
-
Cell Line:MGC-803 and SGC-7901 cells
-
Concentration:10, 20, 30 nM for SGC-7901 cells; 8, 16, 24 nM for MGC-803 cells
-
Incubation Time:48 h
-
Result:A concentration-dependently made cell nuclei brighten, shrink, and vary in size, and when the concentration was 24 nM for MGC-803 cells or 30 nM for SGC-7901 cells, the nucleus appeared broken, showing the morphological characteristics of apoptotic cells and the proportion of dead cells increased.
-
Cell Line:MGC-803 and SGC-7901 cells
-
Concentration:10, 20, 30 nM for SGC-7901 cells; 8, 16, 24 nM for MGC-803 cells
-
Incubation Time:48 h
-
Result:Effectively and dose-dependently induced G2/M phase arrest. After the treatment with 24 nmol/L (MGC-803 cells) or 30 nmol/L (SGC-7901 cells), the percentages of G2/M phase in MGC-803 and SGC-7901 cells were 60% and 74%. While the percentages of G2/M in untreated groups were 33% (MGC-803 cells) and 32% (SGC-7901 cells), respectively.
-
Cell Line:MGC-803 and SGC-7901 cells
-
Concentration:10, 20, 30 nM for SGC-7901 cells; 8, 16, 24 nM for MGC-803 cells
-
Incubation Time:48 h
-
Result:Down-regulated the expression levels of Bcl-2 and Mcl-1 (anti-apoptotic proteins) in a dose-dependent manner, significantly increased the protein levels of cleaved Caspase-3 and Caspase-7.
-
Cell Line:MGC-803 and SGC-7901 cells
-
Concentration:10, 20, 30 nM for SGC-7901 cells; 8, 16, 24 nM for MGC-803 cells
-
Incubation Time:48 h
-
Result:Down-regulated the expression levels of the proliferation related proteins Weel and CDC2 in dose-dependent manners, thus leading to the decrease of cdc2 phosphorylation (thr161). While decreased the expression level of CyclinB1 (a G2 phase related protein), and obviously increased the expression level of p-Histone H3 (a M phase marker protein) in a dose-dependent manner.
-
Cell Line:MGC-803 and SGC-7901 cells
-
Concentration:10, 20, 30 nM for SGC-7901 cells; 8, 16, 24 nM for MGC-803 cells
-
Incubation Time:48 h
-
Result:With the increase of concentrations, increased the expression levels of H3K4me1 and H3K4me2, indicating that inhibited cellular activity of LSD1 in MGC-803 and SGC-7901 cells.
-
Cell Line:MGC-803 and SGC-7901 cells
-
Concentration:10, 20, 30 nM for SGC-7901 cells; 8, 16, 24 nM for MGC-803 cells
-
Incubation Time:48 h
-
Result:Exhibited significant inhibitory effects on the migratory ability of gastric cancer cells MGC-803 and SGC-7901 cells.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c-nu nude mice[1]
-
Dosage:25 mg/kg
-
Administration:25 mg/kg/day; i.p.; 21 days
-
Result:Significantly inhibited the growth of gastric cancer and greatly reduced the weight and volume of the tumor tissues.
Chemical Information
-
CAS No. 3043676-46-3
-
Appearance Solid
-
Molecular Weight 612.76
-
Formula C30H36N4O6S2
-
Color Light yellow to yellow
-
SMILES
COC1=CC(N(C(CSC(N2CCN(CC2)C3=CC=C(C=C3)N)=S)=O)CC4=CC(O)=C(C=C4)OC)=CC(OC)=C1OC
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (163.20 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (4.08 mM); Clear solution; Need ultrasonic
This protocol yields a clear solution of 2.5 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (4.08 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocols
-
Scratch/Wound-Healing Migration Assay
The scratch/wound-healing migration assay measures collective migration of adherent cells into an experimentally created cell-free gap in a confluent monolayer. The readout is generated by imaging the gap immediately after scratching and at later time points, then quantifying reduction in wound area, wound width, or percentage closure as cells move into the denuded region. Gap closure reflects cell migration but may also include cell proliferation, so interpretation should distinguish migration-focused conditions from proliferation-driven closure when possible, such as by using short assay windows, serum-controlled conditions, cell counting, or proliferation controls reported in published protocols.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Cell migration
Cell migration is a method that plays an important role in wound healing, cell differentiation, embryonic development, etc.
-
Neural Crest/Neuronal Cell Migration Explant Assay
Neural crest (NC) and neuronal cell migration explant assays are in vitro systems in which neural tube-derived tissues are cultured to allow premigratory or newly emigrated neural crest cells to undergo epithelial-to-mesenchymal transition (EMT), migrate away from the explant, and form a measurable radial outgrowth that reflects migratory capacity and environmental responsiveness. These assays typically quantify migration by measuring the expansion of cell outgrowth from neural tube or neural plate border explants over time, often comparing early and later timepoints to derive a migration index such as a radius ratio, which reflects net cell dispersal from the explant core. Neural tube explant cultures preserve key aspects of neural crest behavior, including EMT, migration, and early differentiation, making them suitable for assessing intrinsic migratory ability and extrinsic cue dependence. However, studies emphasize that migratory outgrowth from neural tube explants may include non-n
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Chemotaxis Gradient Chamber Assay 1
The chemotaxis gradient chamber assay is based on the principle of observing directional cell migration in response to a stable, linear or quasi-linear concentration gradient of a chemoattractant formed between two fluid reservoirs separated by a narrow observation chamber. Cells placed within the chamber respond to the gradient by polarized movement toward higher chemoattractant concentrations, allowing quantification of chemotactic behavior in real time under microscopy. The classic Zigmond chamber design enables simultaneous visualization of gradient formation and individual cell trajectories, making it suitable for studying leukocyte chemotaxis and other motile cell types in vitro.
-
Under-Agarose Cell Migration Assay
The under-agarose cell migration assay is a classical in vitro chemotaxis method designed to evaluate directed cell movement through a semi-solid agarose matrix toward soluble chemoattractant gradients, enabling visualization and quantification of leukocyte or motile cell migration in a confined 2D-like environment. In this system, cells and chemoattractants are placed in separate wells cut into an agarose gel, allowing diffusion-driven gradient formation that guides directional migration, which is typically assessed by measuring migration distance, cell morphology changes, and accumulation toward the chemoattractant source. This assay has been widely used to study neutrophil and leukocyte chemotaxis as a simple alternative to filter-based migration systems and allows direct microscopic observation of migrating cells under near-physiological confinement conditions.
-
Transwell/Boyden Chamber Migration Assay
The Transwell/Boyden chamber migration assay measures cell movement through a porous membrane separating an upper and lower chamber, usually after a chemoattractant gradient is established by placing cells in the upper chamber and chemoattractant-containing medium in the lower chamber. The readout is generated by quantifying cells that traverse the membrane and appear on the lower membrane surface or in the lower chamber, depending on whether the cell type is adherent or non-adherent. This assay reflects chemotactic or haptotactic migration rather than matrix invasion unless an extracellular-matrix barrier is added to the membrane.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
3D Collagen/Hydrogel Matrix Migration Assay
The 3D collagen/hydrogel matrix migration assay is based on embedding cells within or on top of a fibrillar collagen type I-rich three-dimensional matrix to model in vivo-like extracellular matrix (ECM) architecture, enabling analysis of cell migration through a physically and biochemically relevant scaffold. In contrast to 2D migration systems, cells in 3D matrices interact with fibrillar collagen networks, requiring coordinated adhesion remodeling and proteolytic or non-proteolytic deformation mechanisms to move through confined spaces, thereby providing a more physiologically relevant readout of invasive and migratory behavior in tissue-like environments. Cell movement in 3D collagen matrices is typically quantified by tracking single-cell trajectories, invasion depth, or matrix penetration over time, reflecting combined effects of cytoskeletal dynamics, cell-ECM adhesion turnover, and ECM remodeling. These systems are widely used to study tumor cell invasion and stromal cell motili
-
Cell-Exclusion Zone Migration Assay
The Cell-Exclusion Zone (CEZ) migration assay is an in vitro 2D cell migration method in which a defined cell-free area is created using removable physical barriers such as silicone stoppers, allowing cells to be seeded around the barrier and subsequently migrate into the cleared zone after barrier removal. This approach enables quantification of collective cell migration by monitoring repopulation of the initially cell-free region over time using microscopy-based imaging. Compared with scratch-based wound healing assays, barrier-based exclusion methods are designed to avoid mechanical damage to the extracellular matrix and reduce injury-induced effects on boundary cells, thereby improving interpretability of migration behavior in vitro. The assay readout is typically the progressive reduction in the cell-free area or the number of cells invading the exclusion zone, reflecting coordinated cell motility relevant to physiological processes such as wound healing, epithelial repair, and ca
-
Chemotaxis Gradient Chamber Assay 2
Chemotaxis gradient chamber assays measure directional cell migration in response to a soluble chemical gradient by imaging cells as they move across a defined observation region; the readout is generated from time-lapse cell trajectories, displacement toward the gradient, forward migration index, trajectory plots, rose/polar plots, and statistical tests of non-random directionality. The Dunn chamber is a direct-viewing glass chamber in which cells migrate across a bridge between control and chemoattractant wells, allowing observation of cells in a linear concentration gradient; related direct-viewing formats include the Insall chamber, which supports defined unidirectional gradients and high numerical-aperture microscopy, and the μ-Slide Chemotaxis chamber, which supports long-term live-cell imaging and gradient characterization with fluorescent dye.
Purity & Documentation
-
Data Sheet (281 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.6320 mL | 8.1598 mL | 16.3196 mL | 40.7990 mL |
| 5 mM | 0.3264 mL | 1.6320 mL | 3.2639 mL | 8.1598 mL | |
| 10 mM | 0.1632 mL | 0.8160 mL | 1.6320 mL | 4.0799 mL | |
| 15 mM | 0.1088 mL | 0.5440 mL | 1.0880 mL | 2.7199 mL | |
| 20 mM | 0.0816 mL | 0.4080 mL | 0.8160 mL | 2.0400 mL | |
| 25 mM | 0.0653 mL | 0.3264 mL | 0.6528 mL | 1.6320 mL | |
| 30 mM | 0.0544 mL | 0.2720 mL | 0.5440 mL | 1.3600 mL | |
| 40 mM | 0.0408 mL | 0.2040 mL | 0.4080 mL | 1.0200 mL | |
| 50 mM | 0.0326 mL | 0.1632 mL | 0.3264 mL | 0.8160 mL | |
| 60 mM | 0.0272 mL | 0.1360 mL | 0.2720 mL | 0.6800 mL | |
| 80 mM | 0.0204 mL | 0.1020 mL | 0.2040 mL | 0.5100 mL | |
| 100 mM | 0.0163 mL | 0.0816 mL | 0.1632 mL | 0.4080 mL |